Cargando…

Immune landscape of breast tumors with low and intermediate estrogen receptor expression

Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for ER-positivity (≥1%) is based on likelihood of endocrine trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voorwerk, Leonie, Sanders, Joyce, Keusters, Milou S., Balduzzi, Sara, Cornelissen, Sten, Duijst, Maxime, Lips, Esther H., Sonke, Gabe S., Linn, Sabine C., Horlings, Hugo M., Kok, Marleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182974/ https://www.ncbi.nlm.nih.gov/pubmed/37179445 http://dx.doi.org/10.1038/s41523-023-00543-0

Ejemplares similares

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
por: Steenbruggen, Tessa G, et al.
Publicado: (2021)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
por: Steenbruggen, Tessa G., et al.
Publicado: (2023)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
por: Geurts, V.C.M., et al.
Publicado: (2023)

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer
por: van wagensveld, lilian, et al.
Publicado: (2023)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
por: Voorwerk, Leonie, et al.
Publicado: (2023)

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2021)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Identifying the Tautomeric Form of a Deoxyguanosine-Estrogen Quinone Intermediate
por: Stack, Douglas E.
Publicado: (2015)

Intermediates: ubiquitous species on folding energy landscapes?
por: Brockwell, David J, et al.
Publicado: (2007)

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
por: Nguyen, Bastien, et al.
Publicado: (2019)

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
por: Sobral-Leite, Marcelo, et al.
Publicado: (2019)

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
por: Nederlof, I., et al.
Publicado: (2022)

Dynamic epi‐transcriptomic landscape mapping with disease progression in estrogen receptor‐positive breast cancer
por: Keelan, Stephen, et al.
Publicado: (2023)

Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Bereaved relatives’ experiences during the incurable phase of cancer: a qualitative interview study
por: Wijnhoven, Marleen N, et al.
Publicado: (2015)

Complex challenges for patients with protracted incurable cancer: an ethnographic study in a comprehensive cancer centre in the Netherlands
por: Buiting, Hilde M, et al.
Publicado: (2019)

Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer
por: Li, Jingmei, et al.
Publicado: (2010)

Chemical space, diversity and activity landscape analysis of estrogen receptor binders
por: Naveja, J. Jesús, et al.
Publicado: (2018)

Genomic landscape of single-stranded DNA gapped intermediates in Escherichia coli
por: Pham, Phuong, et al.
Publicado: (2021)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
por: Aswolinskiy, Witali, et al.
Publicado: (2023)

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

The genomic landscape of estrogen receptor α binding sites in mouse mammary gland
por: Palaniappan, Murugesan, et al.
Publicado: (2019)

Estrogen differentially regulates transcriptional landscapes of preoptic and arcuate kisspeptin neuron populations
por: Göcz, Balázs, et al.
Publicado: (2022)

HRD-related morphology discovery in breast cancer by controlling for confounding factors
por: Schirris, Yoni, et al.
Publicado: (2022)

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016)

Interaction of the Double-Strand Break Repair Kinase DNA-PK and Estrogen Receptor-α
por: Medunjanin, Senad, et al.
Publicado: (2010)

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
por: Hudeček, Jan, et al.
Publicado: (2020)

Intermediate Valence States in Lanthanide Compounds
por: Tricoire, Maxime, et al.
Publicado: (2021)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Turning up the heat does not affect quality of life
por: van Driel, Willemien J., et al.
Publicado: (2022)

Friendship during patients’ stable and unstable phases of incurable cancer: a qualitative interview study
por: van Eijk, Michelle, et al.
Publicado: (2022)

IPDmada: An R Shiny tool for analyzing and visualizing individual patient data meta‐analyses of diagnostic test accuracy
por: Wang, Junfeng, et al.
Publicado: (2020)

Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers
por: Hsiao, Tzu-Hung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7kgie95fltep9rm4uvm3t5a1l4